Alvogen Lux Holdings S.à r.l. (“Alvogen”) and Aztiq Pharma Partners S.à r.l. (“Aztiq”) have each subscribed to 2,500,000 newly issued shares of Alvotech (the “Company”) for a price of $10 per share. The 5,000,000 shares were issued pursuant to the terms of settlement agreements between the Company a

AVT06 is the third biosimilar candidate developed by Alvotech to enter clinical studiesEylea® (aflibercept) is used for the treatment of eye disorders and reached global sales of nearly US$10 billion...

The board of directors of Alvotech (the “Company”) has resolved to increase the Company´s share capital by an amount of two hundred seventy thousand seven hundred twenty-one US dollars and sixty-seven...

After the largest debut by an Icelandic company on a U.S. stock exchange, Alvotech is set to list its shares under the ticker symbol “ALVO” on the Nasdaq First North Growth Market in Iceland commencing on June 23. Public listing on Nasdaq First North Growth in Iceland offers Icelandic investors

In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC),  Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June 2022. The Supplement will form part of and must be read and construed in conjunction with the Company

In connection to the filling on Form 20-F with the U.S. Securities and Exchange Commission (SEC),  Alvotech has published a supplement dated 22 June 2022 to the Company Description, dated 21 June...

Alvotech, a public limited liability company (société anonyme), incorporated and existing under the laws of the Grand Duchy of Luxembourg, having its registered office at 9, rue de Bitbourg, L-1273...

- Debut on Nasdaq follows completion of the company’s business combination with Oaktree Acquisition Corp. II, which included a fully committed and upsized $175 million PIPE raised through top-tier investors at $10.00 per share - Alvotech’s mission is to enhance sustainability of the global

Hukyndra ®  offers a comprehensive range of presentations to the EU adalimumab biosimilars market. Adalimumab marks the first molecule introduced through STADA’s partnership with Alvotech to bring biosimilars across immunology, oncology and ophthalmology indications to patients and their caregivers